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Abstract One of the major obstacles in cancer therapy is the
lack of anticancer agent specificity to tumor tissues. The strat-
egy of cell-based therapy is a promising therapeutic option for
cancer treatment. The specific tumor-oriented migration of
mesenchymal stem cells (MSCs) makes them a useful vehicle
to deliver anticancer agents. In this study, we genetically ma-
nipulated bone marrow-derived mesenchymal stem cells with
their lipocalin 2 (Lcn2) in order to inhibit liver metastasis of
colon cancer in nude mice. Lcn2 was successfully
overexpressed in transfected MSCs. The PCR results of
SRY gene confirmed the presence of MSCs in cancer liver
tissue. This study showed that Lcn2-engineered MSCs
(MSC-Lcn2) not only inhibited liver metastasis of colon can-
cer but also downregulated the expression of vascular endo-
thelial growth factor (VEGF) in the liver. Overall, MSCs by
innate tropism toward cancer cells can deliver the therapeutic
agent, Lcn2, and inhibit cancer metastasis. Hence, it could be
a new modality for efficient targeted delivery of anticancer
agent to liver metastasis.
Keywords Mesenchymal stem cells . Lipocalin 2 . Liver
metastasis . Nudemice . Colon cancer
Introduction
Cancer is one of the world most life-threatening and lethal
diseases, and colorectal cancer is the third most common can-
cer and the fourth most frequent cause of cancer death world-
wide [1, 2]. Scientific investigations revealed that many met-
astatic malignancies show strong resistance to conventional
methods of cancer therapy such as surgery, chemotherapy,
and radiotherapy. Therefore, many patients suffering from
cancer are highly exposed to death due to tumor recurrence
and therapy-related harmful complications [3–5]. On the other
hand, cancer treatment methods are usually associated with
many obstacles including the development of long-term side
effects such as cardiac failure, renal injury, musculoskeletal
problems, and pulmonary dysfunction [6, 7]. As a matter of
fact, lack of tumor specificity is the major drawback of con-
ventional cancer therapies. Therefore, numerous studies have
focused on exploring new specific tumor-targeting approaches
to efficiently attack cancerous cells. Recently, cell-based ther-
apies have extensively attracted researchers’ attention. One of
the valuable cells in this regard is mesenchymal stem cells
(MSCs) [8]. MSCs have many therapeutic potentials such as
simplicity of obtaining and in vitro expansion [9], low immu-
nogenicity [10], self-renewality and high migration potential
toward the injury sites [11] These characteristics make them
an appropriate candidate for cellular therapies. However, one
of the interesting properties of MSCs is the specific tumor-
orientedmigration that rendered them to function as a new and
ideal therapeutic vehicle to deliver anticancer agents directly
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to the tumor sites and their metastatic environment [4]. In
support of this notion, genetically modified MSCs with anti-
cancer properties are capable of inhibiting tumor growth in
experimental animal models such as those with glioma
[12–14], melanoma [15], breast [16], prostate [17], and pan-
creatic [18, 19] cancers.
Lipocalin 2 (Lcn2) or neutrophil gelatinase-associated
lipocalin (NGAL) is one of the anticancer molecules
[20–22]. Although the precise role of Lcn2 remained to be
controversial, several studies reported that it is implicated in
pathophysiological phenomena such as inflammation, infec-
tion, injury, asthma, arthritis, and cancer [23]. Additionally,
some other studies demonstrate that Lcn2 inhibits the pro-
neoplastic factor HIF-1a, FA-kinase phosphorylation as well
as vascular endothelial growth factor (VEGF) synthesis [24].
Further studies also confirmed that Lcn2 generates an antitu-
mor effects at least on some sorts of neoplasia such as colon
[20], ovary [21], and pancreas [22].
Based on these observations, in the present study, we hy-
pothesized that genetically Lcn2-modified MSCs would spe-
cifically track the sites of metastasis formation, and target
them through site-specific production of antitumor agent,
i.e., Lcn2. Therefore, by exploiting the innate tendency of
MSCs toward cancer cells, we exploited bone marrow-
derived MSCs as efficient vehicles for the targeted delivery
of expressed Lcn2 toward tumor sites. Here, we report that
Lcn2-engineered MSCs are capable of homing and localizing
into the metastatic liver that further inhibit the liver metastasis
of colon cancer cells in nude mice.
Materials and methods
Cells isolation, expansion, and identification
Human bone marrowMSCs were isolated from the bone mar-
row of healthy human volunteers with informed consent.
MSCs were successfully isolated as described previously
[25] and cultured in 10 % fetal bovine serum Dulbecco’s
modified eagle’s medium (DMEM; Gibco-BRL, Eggenstein,
Germany). The culture dishes were incubated at 37 °C in the
presence of 5%CO2. In order to confirm theMSCs, they were
evaluated by flow cytometry for the expression of surface
markers as described previously [25].
On the other hand, human colon cancer cell line SW48 was
obtained from the National Cell Bank of Iran (Pasteur Institute
of Iran). The cells were cultured in RPMI 1640 medium
(Gibco-BRL, Germany) containing 10 % fetal bovine serum
(Gibco-BRL, Germany) and 1 % penicillin streptomycin so-
lution (10,000 U of penicillin and 10 mg of streptomycin)
inside 25 cm2 cell culture flasks. The flasks were maintained
at 37 °C and 5 % CO2.
Construction of Lcn2 recombinant plasmid and transfection
into MSCs
Following isolation of Lcn2 by PCR, the product was
subcloned into pEGFPN1 vector producing recombinant
pEGFPN1-Lcn2 plasmid. The fidelity of the subcloned se-
quence was evaluated by DNA sequencing. Moreover, the
amplification of a fragment of about 640 bp length via PCR
using Lcn2-specific primers confirmed the translocation of the
Lcn2-coding sequence into the destination vector. Next, the
MSCs were transfected with 2 μg of pEGFPN1-Lcn2 plasmid
using FuGENE HD (Roche, Germany) transfection reagent
according to manufacturer’s protocol. As a control, MSCs
were transfected with pEGFPN1 (MSC-V). The expression
level of Lcn2 was evaluated by reverse transcription PCR
(RT-PCR), enzyme-linked immunosorbent assay (ELISA)
(R&D Systems, Minneapolis, MN, USA), and Western blot
analyses.
RT-PCR and PCR
PCRwas performed in order to clone and evaluate the expres-
sion of Lcn2 and VEGF. To construct the Lcn2 expression
plasmid, the 624-bp-long Lcn2 complementary DNA
(cDNA) was isolated by PCR from primary vector,
pcDNA3.1-Lcn2, using specific forward 5′ACGAATTC-
ACCATGGTGCCCCTAGGTCTCCTGTGGCTG3′ and re-
verse 5 ′TAGGATCCGCCGTCGATACACTGGTC3 ′
primers. The forward primer included both the BamH1 recog-
nition sequence (italicized) and Kozak sequence sites, while
the reverse primer included EcoR1 recognition sequence site
(italicized). PCR condition included a primary denaturation
step of 5 min at 94 °C followed by 38 cycles of 30 s at
94 °C, 42 s at 59 °C, and 30 s at 72 °C and a final extension
step of 3 min at 72 ° C.
To assess the expression of Lcn2 by RT-PCR, total RNA
was extracted using TriPure reagent (Roche, Germany) ac-
cording to manufacturer’s protocol. RNA quality was deter-
mined by electrophoresis. Then, the extracted RNAwas used
at the concentration of 500 ng/μl to construct cDNA using
First-Strand cDNA Synthesis SuperScript kit (Invitrogen,
USA) according to manufacturer’s protocol. Then, PCR was
performed using internal Lcn2 primers, forward 5′TCACCT
CCGTCCTGTTTA3′ and reverse 5′TGGCATACATCTTT
TCGGGT3′. PCR condition included a primary denaturation
step of 4 min at 94 °C followed by 35 cycles of 30 s at 94 °C,
42 s at 57 °C, and 30 s at 72 °C and a final extension step of
2 min at 72 ° C. Finally, PCR products were analyzed by 2 %
agarose gel electrophoresis. β-actin expression was evaluated
for normalization.
PCR was also performed to detect SRY gene using SRY
primers, forward 5′GAATATTCCCGCTCTCCGGAG3′ and
reverse 5′TCTCTGAGTTTCGCATTCTGGGA3′. PCR
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conditions included a primary denaturation step of 4 min at
94 °C followed by 35 cycles of 30 s at 94 °C, 42 s at 58 °C,
and 30 s at 72 °C and a final extension step of 2 min at 72 ° C.
Finally, 7 μl of each PCR product was analyzed by 2 % aga-
rose gel electrophoresis. β-actin expression was evaluated for
normalization.
Additionally, to assess the expression of Lcn2 by RT-PCR,
total RNA was extracted from liver tissues, and cDNA was
synthesized. Then, PCR was performed using internal Lcn2
primers. PCR condition was mentioned above, and PCR prod-
ucts were analyzed by 2 % agarose gel electrophoresis. Also,
to evaluate the VEGF expression, PCR was performed using
internal VEGF primers. Primer set for VEGF included for-
ward 5′TCCATGGATGTCTATCAGCG3′ and reverse 5′
GCTCATCTCTCCTATGTGCT3′. PCR condition included
a primary denaturation step of 4 min at 94 °C followed by
35 cycles of 30 s at 94 °C, 42 s at 59 °C, and 30 s at 72 °C and
a final extension step of 2 min at 72 ° C. The PCR products
were subsequently analyzed by 2 % agarose gel
electrophoresis.
Quantitative real-time PCR
After cell therapy, total RNA was extracted with TriPure re-
agent (Roche, Germany) from liver tissue. The samples were
subjected to quantitative real-time PCR analysis to indicate
the increase in the level of VEGF expression (angiogenesis
marker). First-strand cDNA was generated using 1 μg RNA
using cDNA synthesis kit (Invitrogen, USA) according to the
kit instructions. By performing PCR reactions and establish-
ing proper thermal cycles, quantitative real-time PCR was
performed in triplicate using SYBR Green PCR Master Mix
(Takara, Japan) with real-time PCR 3000 system (Corbett,
Sydney, Australia). PCR conditions included a primary dena-
turation step of 5 min at 94 °C, followed by 40 cycles of 30 s at
94 °C, 40 s at 57 °C, and 30 s at 72 °C and a final extension
step of 4 min at 72 ° C. The cycle threshold (Ct) was calcu-
lated automatically, and normalization was carried out with
the β-actin Ct value.
Western blot analyses
Western blot analysis was performed to evaluate the expres-
sion of Lcn2 in transfected MSCs with pcDNA3.1-Lcn2 vec-
tor at protein level. Denatured samples were run on 10–12 %
SDS-polyacrylamide gel and transbloted onto PVDF mem-
branes. The membranes were incubated with 1:200 dilution
of specific human primary anti-Lcn2 antibody (Santa Cruz
Biotechnology, Inc., Santa Cruz, CA, USA). Following 2–
3 h of incubation at room temperature with primary antibody,
the membranes were washed with Tris-buffered saline con-
taining 0.1 % Tween 20, then incubated with 1:2000 dilution
of HRP-conjugated IgG (Dako, Glostrup, Denmark) as the
secondary antibody (1 h by shaking at room temperature).
Finally, after washing the membrane, a chemiluminescence
solution was used to visualize the expected protein bands on
PVDF membrane.
Experimental liver metastasis
Six-week-old female athymic C57BL/6 nude mice were ob-
tained from Cancer Models Research Center, Cancer Institute
of Iran. To set up experimental liver metastasis, the mice were
anesthetized with ketamine (100 mg/kg)/xylazine (10 mg/kg)
mixture, and the left flank was prepared for sterile surgery. A
small abdominal incision was made in the left flank, and the
spleen was isolated and exteriorized. 3×106 SW48 cells (in
100 μl phosphate-buffered saline (PBS)) were injected into
the spleen with a 27-gage needle. The spleen was turned back
to the abdominal cavity, and the wound was sutured in two
layers. The surgery procedure was shown in supplementary
movie. Several weeks later, the mice were sacrificed. Their
liver tissues were evaluated by hematoxylin and eosin
(H&E) staining; afterwards, the onset of metastasis was iden-
tified on 50th day after tumor cell implantation. To examine
the effect of MSC-Lcn2 on liver metastasis, after beginning of
the experimental liver metastasis, four groups of mice (n=6/
group, according to the similar studies [20, 26]) with
preestablished liver metastasis were injected intravenously
with PBS, 1×106 MSCs, 1×106 MSC-V, and 1×106 MSC-
Lcn2 on day 55. Moreover, two groups of normal mice (with
no metastasis) were injected with PBS and 1×106 MSCs as
the control groups. Finally, on day 65 following tumor cell
injection, to evaluate the presence of tumors in the liver, sam-
ples were collected, fixed with formalin, and embedded in
paraffin for routine H&E staining.
Tumor targeting analysis
In order to investigate whether MSCs migrated to the meta-
static liver, SRY gene was detected by PCR reaction on DNA
samples from metastatic liver tissues of female mice injected
intravenously with MSC-Lcn2, MSC-V, and MSC of male
donor origin, at two different time points on 4th and 10th days
after MSCs intravenous injection. DNA was extracted from
liver tissue by genomic DNA extraction kit (Fermentas, Vil-
nius, Lithuania) according to manufacturer’s protocol follow-
ed by PCR as described above.
Results
MSCs naturally express specific MSC-related cell surface
markers. As reported previously, MSCs express typical anti-
genic profile of surface markers. They are positive for CD166,
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CD105, CD90, and CD73 and negative for CD45 and CD34
[25].
Overexpression of Lcn2 in MSCs
To determine the overexpression of Lcn2 in MSCs, 4 days
post-transfection of the MSCs, GFP was detected by fluores-
cent microscopy (Fig. 1a). RT-PCRwas performed to evaluate
the expression of Lcn2 at messenger RNA (mRNA) level. The
result revealed that MSCs-Lcn2 overexpressed Lcn2 in com-
parison toMSCs-V,MSCs which were transfected with empty
vectors (Fig. 1b). This was further confirmed by Western blot
analysis to detect Lcn2 at protein level (Fig. 1c). Finally, the
results were also confirmed by ELISAwhich were consistent
with those of Western blot analysis (data not shown). To de-
termine transient overexpression of Lcn2 in MSCs, RT-PCR
was performed at different time points (1, 2, 3, 4, 7, 8, and
10 days post-transfection). The basal expression of Lcn2 in-
creased to the highest expression level at day 4, while it
decreased thereafter until day 10 (Fig. 2). These results indi-
cate the transient overexpression of Lcn2.
MSC-Lcn2 inhibits metastasis of liver
Next, we tested the therapeutic potential of MSCs as cellular
vehicles to deliver recombinant Lcn2 toward metastatic site.
Initiation signs of metastasis were observed histologically at
day 50 post-injection (Fig. 3a). The design of the experiment
is shown in Fig. 3b. After intravenous injection of transfected
MSCs, interestingly, MSC-Lcn2 showed inhibitory effects on
liver metastasis growth in four of five experimental animals
(Table 1. group no. 6). In contrast, there was no significant
influence on liver metastasis growth in mice which were
injected with MSC-V, MSC, and PBS (Table 1. group nos.
3, 4, 5). No liver metastases were observed in two control
groups of normal mice injected with MSC and PBS. Next,
to determine whether human Lcn2 was expressed in the liver,
RT-PCR was performed on day 4 after injection. As shown in
Fig. 3c, PCR band of Lcn2 was only detected in the liver of
those mice transplanted with MSC-Lcn2. This suggests that
MSC-Lcn2 expresses and delivers human Lcn2 to the meta-
static liver.
MSCs migrate toward metastatic liver
Detection of human Y chromosome-specific SRY gene is one
of the well-known methods for tracking cells. Based on PCR
detection of SRY gene 4 days after injection, MSCs-Lcn2,
MSCs-V, and MSCs were found in the metastatic liver and
to a low amount in the liver of mice with no metastasis
(Fig. 4a). Moreover, 10 days after injection, MSCs-Lcn2,
MSCs-V, and MSCs were maintained in the metastatic livers
of mice, and no MSCs were detected in the livers of normal
mice (Fig. 4b). Overall, these results indicate that MSCs are
capable of homing and localizing into metastatic tissue after
systemic injection.
MSC-Lcn2 reduces VEGF expression in the metastatic liver
Angiogenesis is an essential process for tumor growth and
dissemination that is mainly stimulated by vascular endothe-
lial growth factor (VEGF), a key angiogenic activator. As
shown in Fig. 5a, the basic level of VEGF expression in-
creased in metastatic liver tissues of mice treated with MSC-
V and MSC in comparison with the normal liver tissues. In
contrast, VEGF expression level was reduced in metastatic
liver tissues of mice treated withMSC-Lcn2.Moreover, based
on quantitative real-time PCR, VEGF expression was signif-
icantly downregulated in metastatic liver tissues of mice treat-
ed with MSC-Lcn2 compared to MSCs and MSCs-V. These
results suggest that Lcn2 inhibits liver metastasis through
downregulation of angiogenesis (Fig. 5b).
Fig. 1 Overexpression of Lcn2 in MSCs transfected with recombinant
pEGFPN1-Lcn2 plasmid. a GFP expression in transfected MSCs was
detected by fluorescent microscopy. b Upper image: RT-PCR analysis
showed Lcn2 overexpression in transfected MSCs with recombinant
pEGFPN1-Lcn2 plasmid (MSC-Lcn2) in comparison with the basal
expression level of Lcn2 that was indicated in MSC-V which was
transfected with empty vectors. Lower image: Expression of β-actin
was used for normalization. M, 100 bp DNA marker. c Western blot
analysis of Lcn2 protein expression in pcDNA3.1-Lcn2 transfected
MSCs. MSC-Lcn2 revealed high levels of Lcn2 protein overexpression
compared to the basic Lcn2 protein expression byMSC-V. Lower image:
Assessment of β-actin expression as a control for both groups
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Discussion
Although there have been significant improvements in the
cancer treatment methods, cancer remains one of the top
life-threatening diseases in which metastasis of cancer cells
to vital organs is the major cause of death. Current cancer
therapies lack sufficient specificity to tumors; therefore, they
posed various side effects on normal tissues. To overcome
these limitations, novel approaches have recently focused on
selectively target tumors by applying various drug delivery
systems such as stealth liposome [27], magnetic nanoparticles
[28], and peptides [29].
In the present study, we exploited Lcn2-engineered MSCs
as a cellular vector to specifically deliver the antitumor gene
into the metastatic liver relying on the intrinsic tumor-oriented
homing capacity of MSCs. Additionally, since Lcn2 acts as an
antitumoral and antimetastatic agent in some cancers [20–22],
here, we genetically manipulated MSCs with Lcn2 to target
Fig. 2 Transient expression of
Lcn2 in MSCs transfected with
recombinant pEGFPN1-Lcn2
plasmid (MSC-Lcn2). Upper
image: RT-PCR analysis of the
Lcn2 expression levels up to
7 days after transfection of MSCs
with recombinant plasmid
showed the highest expression
level on day 4 and a decrease in
the expression thereafter. Lower
image: Expression of β-actin was
used for normalization.M, 100 bp
DNA marker
Fig. 3 Liver metastasis after intrasplenic injection of SW48. a 50 days
after intrasplenic injection, tumor cells were visible in the liver by H&E
staining in comparison with control group. Cancer cells are marked by
star (*), and liver cells are marked by arrow (→). b Three million SW48
cells were injected intrasplenic at day 0, and initiation of liver metastases
was at day 50 post-injection. Subsequently, MSCs were injected into the
tail vein on day 55, and finally, the mice were sacrificed on day 65 to
evaluate the presence of tumor cells in the liver. c Evaluation of gene
delivery into liver metastases upon systemic MSC-Lcn2 administration
by RT-PCR. Presence of Lcn2 within the liver samples confirmed the
capability of MSC-Lcn2 to deliver Lcn2 into metastatic livers after
systemic administration (lane 4), whereas no expression of Lcn2 was
detected in the livers of mice injected with MSC-V, MSC (lanes 2 and
3), and control group (lane 1)
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liver metastasis through site-specific production of Lcn2 that
exerts inhibitory effects on tumor cells.
We transfectedMSCswith pEGFPN1 plasmid vectors. The
results revealed that MSCs-Lcn2 successfully overexpress
Lcn2 at both mRNA and protein levels. As a matter of fact,
employing the plasmid expression system is beneficial be-
cause it offers easy transfection condition and transient ex-
pression. Considering the fact that the precise role of Lcn2 is
not fully understood, we hypothesize that continuous expres-
sion of Lcn2 may be harmful. Therefore, we applied plasmid
expression system in our study in order to transiently overex-
press Lcn2.
Due to the importance of stem cell migration in cancer
therapy, we evaluated the migratory property of MSCs. De-
tection of SRY gene is one of the well-known methods for
tracking the cells in cellular therapy. Having applied this meth-
od at two different time points, i.e., 4 and 10 days after injec-
tion, the results revealed that MSCs-Lcn2, MSCs-V, and
Table 1 Antitumor effect of MSC-Lcn2 on the growth of liver
metastasis
Liver
metastasis/
alive mice
Liver
metastasis
Alive
until
65 days
Failed
mice
Total
mice per
group
Groups No.
0/6 0 6 0 6 PBS 1
0/5 0 5 1 6 MSCs 2
3/4 3 4 2 6 SW48/PBS 3
4/5 4 5 1 6 SW48/MSCs 4
3/4 3 4 2 6 SW48/MSCs-
pEGFPN1
5
1/5 1 5 1 6 SW48/MSCs-
pEGFPN1-
Lcn2
6
Fig. 4 Tumor homing ability of MSCs into the metastatic liver. a Upper
image: PCR analysis of SRY gene on day 4 after i.v. injection of MSCs
showed the presence of MSC, MSC-V, and MSC-Lcn2 in the metastatic
liver (lanes 4, 5, and 6), and also the presence ofMSCs in the normal liver
(lane 2). Lanes 1 and 3: No MSC was injected, and MSCs were not
detected in the liver. Lower image: Expression of β-actin was used for
normalization.M, 100 bp DNA marker. b Upper image: PCR analysis of
SRY gene on day 10 after i.v. injection of MSCs showed the maintenance
of MSC, MSC-V, and MSC-Lcn2 in the metastatic liver (lanes 4, 5, and
6), and MSCs in the liver of normal mice were cleared away (lane 2).
Lanes 1 and 3: NoMSCwas injected, andMSCs were not detected in the
liver. Lower image: Expression of β-actin was used for normalization.M,
100 bp DNA marker
Fig. 5 Effects of MSC-Lcn2 on the angiogenesis of liver metastasis. a
Upper image: RT-PCR analysis of angiogenic factor, VEGF, showed a
reduction in VEGF expression in liver tissues of mice treated with MSC-
Lcn2 (lane 5) compared to the high levels of VEGF expression in
metastatic liver tissues of mice treated with MSC-V, MSC (lanes 3 and
4), and nontreated mice (lane 2). There was a basic VEGF expression in
the normal liver as a control (lane 1). Lower image: Expression ofβ-actin
was used for normalization.M, 100 bp DNAmarker. b Quantitative real-
time PCR analysis of VEGF showed that downregulation of VEGF
expression was significantly higher in MSC-Lcn2/SW48 compared to
MSCS/SW48 and MSCS-V/SW48 (Mean±SD; ***p<0.001)
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MSCs migrated actively toward the metastatic liver. More-
over, systemically injected MSCs clear away from the liver
tissue of normal mice after 10 days, suggesting no necessity
for the existence of these cells (MSCs) in normal tissues. Re-
cently, several research groups have proved that genetically
engineered MSCs are effective in cancer treatment of animal
models bearing different tumors. For instance, IL-2 and
EphA2-engineered MSCs are practical to suppress glioma tu-
mor [12, 14]. Furthermore, some studies proved that IL-12,
IF-β, and TRAIL-engineered MSCs are capable of reducing
lungmetastasis of breast and prostate cancer [1, 12, 17]. In this
study, we similarly observed significant inhibition of liver
metastasis of colon cancer in nude mice injected with MSC-
Lcn2. We evaluated the effect of transient overexpression of
Lcn2 in genetically engineered MSCs, and we showed the
overexpression of Lcn2 by MSCs in vitro throughout 10 days
after transfection. In this regard, we evaluated the therapeutic
effect of Lcn2 after 10 days in nude mice. Interestingly, after
10 days, we have got a positive result that confirms the ther-
apeutic effect of Lcn2 in a short period of time (10 days). This
revealed the promising effect of Lcn2 in cancer treatment.
Moreover, generating fast effectiveness over a short time is
also a vital factor in cancer treatment. Notably, the findings of
this study supported the foregoing property. Moreover, we
observed that MSCs-Lcn2 are able to migrate and reduce liver
metastasis. However, the effect of Lcn2 on the survival of
mice awaits elucidation. In support of our findings, Lee et al.
[20] ectopically expressed Lcn2 in the KM12SM colon cancer
cell line by a lentiviral vector, and a clear inhibitory effect on
liver metastasis of colon cancer was observed in animal
models. Moreover, Tong et al. [22] demonstrated that stable
Lcn2 overexpression (MIAPaCa-2 and PANC-1) significantly
inhibited cell adhesion and invasion in vitro and reduced pan-
creatic cancer growth in vivo. However, Li et al. [30] reported
that downregulation of Lcn2 suppressed human esophageal
carcinoma SHEEC cell invasion in vivo. These controversial
reports regarding the role of Lcn2 depend mainly on the type
of cancer.
Vascular endothelial growth factor (VEGF) is one of the
key cancer-promoting molecules capable of intensifying ma-
lignancy through increasing the rate of angiogenesis. Taking
this into consideration in the present study, we observed that
VEGF expression was reduced in metastatic liver tissues of
mice treated with MSCs-Lcn2 in comparison with those treat-
ed with MSCs-V, MSCs, and PBS. This showed the elevated
levels of VEGF in their metastatic liver tissues. In support of
this notion, Tong et al. [22] showed that Lcn2 suppressed
VEGF expression and angiogenesis in pancreatic cancer.
Moreover, Venkatesha et al. reported that Lcn2 inhibits Ras-
induced VEGF production [31]. In contrast, Yang et al. [32]
proved that Lcn2 promotes angiogenesis in breast cancer.
We used MSCs as means of target delivery of recombinant
Lcn2 toward colon cancer cells, and study the potential
capability of these engineered cells to inhibit liver metastasis.
Our initial results not only indicated that MSCs-Lcn2 migrat-
ed toward cancer cells, but they also inhibited metastasis in the
liver. This study highlights the importance of MSCs as a new
vehicle to perform target delivery of anticancer molecules at
least on colon cancer cells. Further comprehensive studies are
indeed required in this regard. It is suggested that further stud-
ies mainly focus on continuous Lcn2 overexpression in stable
clones for a longer period of time.
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